MBX Biosciences Inc（MBX）資訊與事件MBXMBX Biosciences Inc

MBX Biosciences Doses First Patient in Phase 3 Trial

MBX Biosciences announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical trial evaluating once-weekly canvuparatide for the treatment of chronic hypoparathyroidism.

MBX Biosciences Reports Clinical Data for MBX 4291

"The second quarter was highlighted by important milestones across our pipeline, including a first look at clinical data for MBX 4291 supporting its potential for true once-monthly dosing in obesity," said Steve Hoerter, Chairman and Chief Executive Officer of MBX Biosciences. "In addition, we were proud to present the full Phase 2 and one-year OLE data for once-weekly canvuparatide, which demonstrated sustained benefit and the potential to become a best-in-class treatment for patients with chronic hypoparathyroidism. Now we look forward to dosing the first patients in our Phase 3 trial of canvuparatide this quarter and to presenting 12-week multiple ascending dose data for MBX 4291 in the fourth quarter. With a strong balance sheet and an experienced team, we continue to leverage our proprietary PEP platform to develop differentiated, long-acting peptide therapies with the potential to meaningfully improve patients' lives."

WTI Crude Oil Price Jumps About 10% to $80

Fast-unraveling ceasefire between Iran and U.S. amid continued dispute over the control of transit through the Strait of Hormuz has reverberated across the asset classes in a predictable fashion on Monday.  WTI Crude Oil spiked about 10% toward $80 per barrel - the highest level in nearly a month - as traders repriced the assumption of US-Iran truce.  In turn the higher inflation expectations feedback loop punished the Treasury markets across the curve, with the benchmark 10-year yield topping 4.6% for the first time since late May and CME FedWatch tool showing swaps markets repricing the probability of a Fed rate hike as soon as this month at a near coin flip.  Higher funding costs then weighed on the large-cap growth areas of the equity market, with AI-buildout positive sectors - i.e. semiconductors, semiconductor equipment, hardware, and communications stocks - punished and the more-defensively geared Utilities and Consumer Staples being rewarded.  Energy, which is still the best performing sector in the S&P 500 this year, also saw outsized gains as the best performing sector in the index, with State Street Energy Select Sector SPDR ETFrising 3% to its best level in a month.In the opening hour of the evening session, S&P e-minis, and NASDAQ 100 contracts remain under pressure with declines of 0.2% and 0.3% respectively.   WTI Crude Oil remains bid just shy of $79 per barrel.   Elsewhere in commodities, gold and silver futures are trading near two-week lows as the U.S. dollar continues to benefit from expectations of higher short-term rates.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER -Lulu's Fashion Loungeup 27.9% after announcing review of strategic alternativesVision Marine Technologiesup 19.1% after Q3 pre-announcementTrex Companyup 6.1% after above-consensus revenue pre-announcementCentrus Energyup 2.0% After being initiated at buy at TruistWeatherfordup 2.0% on considered  re-domestication from Ireland to DelawareDOWN AFTER EARNINGS -FB Financialdown 1.0%ALSO LOWER -MBX Biosciencesdown 7.6% after announcing leadership transitionPenguin Solutionsdown 6.2% after announcing a convertible note offeringUnited Maritimedown 3.4% after equity offeringErascadown 1.8% after equity offering